Pfizer’s Allergan Acquisition Paves The Way For A Split – But Delayed
Executive Summary
Pfizer’s $160bn deal to buy Allergan and redomicile in Ireland could position the company better for an eventual split. But Pfizer said it will now wait until 2018 to decide if it will break up the company, disappointing some investors.
You may also be interested in...
Stronger Together: Pfizer Decides Against A Split
The pharma giant's decision not to break up into two separate publicly traded companies as it has been contemplating for several years reflects an improved growth outlook and the inability to unlock trapped value. Now Pfizer can finally get on with business.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.